Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | The potential role of live bacterial therapies in renal cell carcinoma

Hedyeh Ebrahimi • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Cabozantinib CBM588 Checkpoint Inhibitors Nivolumab

Hedyeh Ebrahimi, MD, MPH, City of Hope Comprehensive Cancer Center, Duarte, CA, comments on the emerging role of live bacterial products in renal cell carcinoma (RCC). A Phase I trial (NCT05122546) of CBM588 is underway, aiming to escalate dosing, with the goal of a future Phase III trial to determine the efficacy of modulating the gut microbiome in patients with RCC. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hedyeh Ebrahimi

Phase I trial of cabozantinib and nivolumab ± CBM588 in metastatic RCC
0:46
Phase I trial of cabozantinib and nivolumab ± CBM588 in metastatic RCC
Hedyeh Ebrahimi • 14 Feb 2025
Developing CBM588, a novel bacterial product, for renal cell carcinoma
0:37
Developing CBM588, a novel bacterial product, for renal cell carcinoma
Hedyeh Ebrahimi • 14 Feb 2025

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals